Standout Papers
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks (2006)
- The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial (2006)
Immediate Impact
11 from Science/Nature 69 standout
Citing Papers
CAR immune cells: design principles, resistance and the next generation
2023 StandoutNature
CAR T therapy beyond cancer: the evolution of a living drug
2023 StandoutNature
Works of E. Hessey being referenced
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
2010
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
2006 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| E. Hessey | 1674 | 703 | 447 | 719 | 8 | 2.3k | |
| Tim Shaw | 1289 | 565 | 420 | 883 | 15 | 2.4k | |
| Mark C. Totoritis | 1223 | 461 | 309 | 858 | 15 | 2.1k | |
| Matthew Cravets | 1077 | 466 | 326 | 604 | 6 | 1.9k | |
| J-C Becker | 1648 | 427 | 362 | 478 | 17 | 2.0k | |
| L Szczepański | 1622 | 711 | 529 | 1033 | 18 | 3.9k | |
| D. Close | 1456 | 539 | 378 | 1166 | 25 | 2.9k | |
| Anke M. van Gestel | 3237 | 576 | 575 | 590 | 23 | 3.6k | |
| M. Lange | 1628 | 276 | 230 | 563 | 7 | 2.2k | |
| Arthur F. Kavanaugh | 2731 | 525 | 462 | 1024 | 27 | 3.6k | |
| M V van Krugten | 1630 | 333 | 226 | 421 | 19 | 2.0k |
All Works
Loading papers...